☆ 4.8 Article

Competent immune responses to SARS-CoV-2 variants in older adults following two doses of mRNA vaccination

NATURE COMMUNICATIONS (2022)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

Correlates of protection against SARS-CoV-2 in rhesus macaques

Katherine McMahan et al.

Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. Garcia-Beltran et al.

Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Rachna T. Shroff et al.

Summary: Cancer patients showed diminished immune responses to the BNT162b2 mRNA vaccine compared to the control group, but a third dose of the vaccine was found to be safe and significantly improved humoral immunity against SARS-CoV-2.

NATURE MEDICINE (2021)

Add to Collection

Letter Microbiology

A SARS-CoV-2 Variant with L452R and E484Q Neutralization Resistance Mutations

Michelle Verghese et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas et al.

Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study

Jingxin Li et al.

Summary: The messenger RNA vaccine candidate BNT162b1, encoding the receptor-binding domain of the SARS-CoV-2 spike protein, showed safety and high levels of humoral and T cell responses in an Asian population, including younger and older Chinese adults. Local reactions and systemic events post-vaccination were generally dose-dependent, transient, and mild to moderate.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications

Salim S. Abdool Karim et al.

Summary: The emergence of SARS-CoV-2 variants, including B.1.1.7 (VOC-202012/01), 501Y.V2 (B.1.351), and P.1 (B.1.1.28.1), has raised concerns about worsening Covid-19 and potential escape from vaccine-induced immunity.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Public, Environmental & Occupational Health

Monitoring differences between the SARS-CoV-2 B.1.1.7 variant and other lineages

Britta L. Jewell

LANCET PUBLIC HEALTH (2021)

Add to Collection

Article Immunology

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

Ruoke Wang et al.

Summary: Research shows that the South African B.1.351 variant exhibits the highest resistance to current monoclonal antibodies and convalescent plasma from COVID-19-infected individuals, and the molecular basis for this resistance and potential antibody escape has been identified.

IMMUNITY (2021)

Add to Collection

Article Multidisciplinary Sciences

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Dami A. Collier et al.

Summary: Elderly individuals, especially those above eighty, show lower immune responses and neutralization abilities against variants of concern after the first vaccine dose, but this improves after the second dose. They have higher frequencies of spike-specific memory B cells but reduced somatic hypermutation of class-switched cells. Production of interferon-gamma and interleukin-2 by SARS-CoV-2 spike-specific T cells is lower in older participants, predominantly by CD4 T cells.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Galit Alter et al.

Summary: The Ad26.COV2.S vaccine has shown clinical efficacy against symptomatic COVID-19, including the B.1.351 variant, but there is uncertainty regarding its immunogenicity against SARS-CoV-2 variants. The study found that neutralizing antibody responses were reduced against the B.1.351 and P.1 variants, while non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants.

NATURE (2021)

Add to Collection

Article Immunology

SARS-CoV-2 variants of concern partially escape humoral but not T- cell responses in COVID-19 convalescent donors and vaccinees

Daryl Geers et al.

Summary: This study suggests that some variants might partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 vaccination, but the S-specific CD4(+) T-cell activation is not affected by the mutations in the B.1.1.7 and B.1.351 variants.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Review Geriatrics & Gerontology

COVID-19 in older people: a rapid clinical review

Fiona E. Lithander et al.

AGE AND AGEING (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Alba Grifoni et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Mingfeng Liao et al.

NATURE MEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Qianqian Li et al.

CELL (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting

Fran Robson et al.

MOLECULAR CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Carolyn Rydyznski Moderbacher et al.

CELL (2020)

Add to Collection

Article Immunology

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity

Tyler J. Ripperger et al.

IMMUNITY (2020)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Public, Environmental & Occupational Health

COVID-19 mortality risk for older men and women

N. David Yanez et al.

BMC PUBLIC HEALTH (2020)

Add to Collection

Review Geriatrics & Gerontology

Immunosenescence and human vaccine immune responses

Stephen N. Crooke et al.

IMMUNITY & AGEING (2019)

Add to Collection

Article Immunology

Defective Transcriptional Programming of Effector CD8 T Cells in Aged Mice Is Cell-Extrinsic and Can Be Corrected by Administration of IL-12 and IL-18

Mladen Jergovic et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Lifelong CMV infection improves immune defense in old mice by broadening the mobilized TCR repertoire against third-party infection

Megan J. Smithey et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)

Add to Collection

Review Immunology

The twilight of immunity: emerging concepts in aging of the immune system

Janko Nikolich-Zugich

NATURE IMMUNOLOGY (2018)

Add to Collection

Review Immunology

Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis

Barnaby Young et al.

VACCINE (2017)

Add to Collection

Article Biotechnology & Applied Microbiology

Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans

Anne Chauvat et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)

Add to Collection

Article Virology

Aged Mice Exhibit a Severely Diminished CD8 T Cell Response following Respiratory Syncytial Virus Infection

Ross B. Fulton et al.

JOURNAL OF VIROLOGY (2013)

Add to Collection

Article Immunology

Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years

Kenneth E. Schmader et al.

CLINICAL INFECTIOUS DISEASES (2012)

Add to Collection

Article Immunology

Repeated In Vivo Stimulation of T and B Cell Responses in Old Mice Generates Protective Immunity against Lethal West Nile Virus Encephalitis

Jennifer L. Uhrlaub et al.

JOURNAL OF IMMUNOLOGY (2011)

Add to Collection

Article Immunology

Key role of T cell defects in age-related vulnerability to West Nile virus

James D. Brien et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2009)

Add to Collection

Article Immunology

Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus

Eric J. Yager et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2008)

Add to Collection

Article Immunology

Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells

Daniela Frasca et al.

JOURNAL OF IMMUNOLOGY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.